Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials

Dermatology and Therapy
Eric L Simpson

Abstract

Patients with moderate-to-severe atopic dermatitis (AD) report a multidimensional disease burden that includes impaired health-related quality-of-life (HRQoL). Changes in overall health status and specific dimensions that contribute to HRQoL were evaluated in adults with moderate-to-severe AD who participated in phase 3 clinical trials of dupilumab, which is a fully human monoclonal antibody that inhibits signaling of cytokines IL-4 and IL-13. Two dupilumab phase 3 clinical trials of identical design included the 5-dimension 3-level EuroQol (EQ-5D) as a measure of HRQoL. EQ-5D data from the two trials were pooled in an analysis that, using analysis of covariance, compared subcutaneous dupilumab 300 mg once weekly (qw) or every 2 weeks (q2w) versus placebo for EQ-5D utility score change from baseline overall and for clinical responders. The proportions of patients who reported different levels of problems on the individual dimension of the EQ-5D were also compared by treatment group. Patients (n = 1379) were 57.9% male with a mean (SD) age of 38.3 (14.3) years; baseline EQ-5D utility scores ranged from 0.611 to 0.629 across treatment groups. EQ-5D least squares mean change from baseline at week 16 was 0.031 with placebo, and was...Continue Reading

References

Oct 17, 2015·Nature Reviews. Drug Discovery·Namita A GandhiGeorge D Yancopoulos
Jan 19, 2016·Journal of the American Academy of Dermatology·Eric L SimpsonVera Mastey
Oct 4, 2016·The New England Journal of Medicine·Eric L SimpsonUNKNOWN SOLO 1 and SOLO 2 Investigators

❮ Previous
Next ❯

Citations

Sep 22, 2017·Dermatology and Therapy·Andreas KuznikSean D Sullivan
Aug 31, 2017·The Journal of Dermatological Treatment·Dylan E LeeVivian Y Shi
Sep 14, 2018·Journal of the American Association of Nurse Practitioners·Susan J TofteMarius Ardeleanu
Feb 15, 2019·Vaccines·John Foerster, Aleksandra Molęda
Jun 22, 2018·Journal of Cutaneous Medicine and Surgery·Alanna C BridgmanAaron M Drucker
Jan 27, 2019·Experimental and Therapeutic Medicine·Diana Deleanu, Irena Nedelea
Jul 14, 2020·Allergy·Pauline AzzanoPhilippe Bégin
Jul 22, 2018·American Journal of Clinical Dermatology·James E Frampton, Hannah A Blair
Sep 2, 2018·Current Allergy and Asthma Reports·Bridget P Kaufman, Andrew F Alexis
Jun 23, 2018·Nature Reviews. Disease Primers·Stephan WeidingerAlan D Irvine
Jun 8, 2019·The Journal of Dermatological Treatment·Giuseppe PistoneMaria Rita Bongiorno
Dec 29, 2020·JAAD Case Reports·Marissa AyasseJonathan I Silverberg
Mar 5, 2021·Pharmacology & Therapeutics·Xiaoliang YangKenji Kabashima
Mar 3, 2021·Journal of the European Academy of Dermatology and Venereology : JEADV·N MohrM Augustin
Aug 3, 2020·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Jonathan I SilverbergJessica J Jalbert
Nov 10, 2020·Dermatitis : Contact, Atopic, Occupational, Drug·Jonathan I SilverbergAbhijit Gadkari
Jan 23, 2020·Actas dermo-sifiliográficas·M Munera-Campos, J M Carrascosa
Nov 13, 2021·Dermatology and Therapy·Marjolein de Bruin-WellerAna B Rossi

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02277743
NCT02277769

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.